CytoSorbents Corporation (CTSO)

[pharmeng]

The FAQ really makes me question what is going on with hospital sales in Germany.

" If CytoSorb® became standard-of-care for the treatment of sepsis, just one hospital would account for potentially $1 to $3 million in CytoSorb® revenue."

So one hospital could generate more sales than they currently get per quarter. They have been working with certain hospitals for close to 5 years (counting the European sepsis trial). Why can't all these hospitals combined come close to generating the income a single hospital could supposedly provide?

This criticism is coming from a lot of us who have been familiar with this stock for years. For me, I had to ask myself, how much longer can I say "i'm long, so it's ok that it takes time". It's a question of is CTSO the best investment at this point in time, when they are many other promising biotechs. Situations change, but I just don't feel like CTSO is the most compelling investment at this time.